GlaxoSmithKline Purchases Ventana System for Automating DNA Microarray Analysis | GenomeWeb

NEW YORK, July 18 – Ventana Medical Systems said Wednesday that GlaxoSmithKline has chosen its Discovery in situ hybridization and immunohistochemistry system for use in DNA and protein expression experiments.

GlaxoSmithKline will install six to eight of Ventana’s systems in its European and North American research facilities, Ventana CEO Christopher Gleeson told GenomeWeb. The two companies will also collaborate to develop improvements in tissue gene expression profiling methods.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.